A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Inclusion Criteria: * Voluntarily provision of written, signed, and dated (personally or via a legally authorized representative) informed consent to participate in the study. * Initiation of treatment with lanadelumab in accordance with current product labelling. Decision to start treatment with lanadelumab must be made before and be independent from enrollment in the study. * Availability of information for HAE attack-related variables assessed at study enrollment for the previous three months. * Ability to use a smartphone for data collection in this study. Exclusion Criteria: * Inability to provide written, signed, and dated informed consent. * Participation in the study not considered appropriate by the treating physician/investigator. * Contraindication to treatment with lanadelumab according to current product labelling. * Pregnant or breastfeeding. * Concomitant exposure to any investigational therapy (including medications not used for HAE). * Current or planned participation in other interventional studies.